Pharmacoeconomic review report: Safinamide (Onstryv) (Valeo Pharma Inc.) indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing "OFF" episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD.

Safinamide mesylate is a monoamine oxidase B (MAO-B) inhibitor used as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing OFF episodes while on a stable dose of levodopa. It is available as 5...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) CADTH 2020, May 2020
Edition:	Final (with redactions)
Series:	CADTH common drug review
Subjects:	Drug Therapy, Combination / Economics Parkinson Disease / Drug Therapy Canada Monoamine Oxidase Inhibitors / Economics Cost-benefit Analysis Antiparkinson Agents / Economics Antiparkinson Agents / Therapeutic Use Monoamine Oxidase Inhibitors / Therapeutic Use Alanine / Economics Alanine / Therapeutic Use
Online Access:	http://www.ncbi.nlm.nih.gov/books/NBK564239
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa